Endologix Inc (ELGX) - Medical Equipment - Deals and Alliances Profile

Endologix Inc (ELGX) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME92D
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company's AAA products are built on traditional minimally-invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform. The company's EVAR products include AFX endovascular AAA system Vela Proximal Endograft and Intuitrak endovascular AAA system; and EVAS products comprise Nellix endovascular aneurysm sealing system. It has manufacturing facility in Irvine. The company sells its products to hospitals in the US and Europe through direct sales force and through third-party international distributors and agents in other parts of the world. Endologix is headquartered in California, the US.

Endologix Inc (ELGX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Endologix Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Endologix Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Endologix Inc, Medical Equipment, Deal Details 12

Venture Financing 12

TriVascular Raises USD 2 Million In Venture Financing 12

TriVascular Raises USD 40 Million In Series E Financing 13

TV2 Raises USD 0.07 Million In Venture Financing 15

Trivascular Raises Funds Through Initial Tranche Of Series D Financing 16

TriVascular Raises USD 7.2 Million In Venture Financing 18

Partnerships 19

Endologix Enters into Co-Development Agreement with Japan Lifeline 19

Equity Offering 20

Endologix Plans to Raise Funds through Public Offering of Shares 20

Endologix Raises USD210 Million in Private Placement 21

Endologix Plans to Raise USD100 Million in Public Offering of Securities 22

Endologix Plans to Raise USD46.2 Million in Equity Offering of Shares 23

TriVascular Technologies Completes IPO For USD 89.7 Million 24

Endologix Completes Public Offering Of Common Stock For USD 40 Million 26

Debt Offering 27

Endologix Raises USD125 Million in Public Offering of 3.25% Notes Due 2020 27

TriVascular Raises USD10 Million in Private Placement 29

Endologix Completes Public Offering Of Notes Due 2018 For USD 86.3 Million 30

Acquisition 32

Endologix Acquires TriVascular Technologies 32

Endologix Inc-Key Competitors 34

Endologix Inc-Key Employees 35

Endologix Inc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Oct 02, 2018: Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range 37

Aug 09, 2018: Endologix reports second quarter 2018 financial results 38

May 02, 2018: Endologix Announces First Quarter 2018 Financial Results 39

Feb 21, 2018: Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results 40

Nov 07, 2017: Endologix Reports Third Quarter 2017 Financial Results 42

Aug 02, 2017: Endologix Reports Second Quarter 2017 Financial Results 43

May 04, 2017: Endologix Reports First Quarter 2017 Financial Results 44

Feb 22, 2017: Endologix Reports Results for the Fourth Quarter and Full Year 2016 45

Corporate Communications 47

Aug 15, 2018: Endologix appoints Jeffrey S. Brown as Chief Operations Officer 47

Jun 25, 2018: Endologix Names Jeffry Fecho As Chief Quality Officer 48

May 02, 2018: Endologix Names John Onopchenko As Chief Executive Officer 49

Feb 21, 2018: Endologix Announces Resignation Of John McDermott As Chief Executive Officer 50

Jan 29, 2018: Endologix Names Greg Morrow As Chief Marketing Officer 51

Jan 29, 2018: Endologix Appoints Greg Morrow as Chief Marketing Officer 52

Oct 19, 2017: Endologix Appoints John Onopchenko as Chief Operating Officer 53

Feb 06, 2017: Endologix Announces Appointment of Dan Lemaitre as Chairman of the Board 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

Endologix Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Endologix Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Endologix Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Endologix Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

List of Tables

Endologix Inc, Medical Equipment, Key Facts, 2017 2

Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Endologix Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Endologix Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Endologix Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Endologix Inc, Deals By Market, 2012 to YTD 2018 9

Endologix Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

TriVascular Raises USD 2 Million In Venture Financing 12

TriVascular Raises USD 40 Million In Series E Financing 13

TV2 Raises USD 0.07 Million In Venture Financing 15

Trivascular Raises Funds Through Initial Tranche Of Series D Financing 16

TriVascular Raises USD 7.2 Million In Venture Financing 18

Endologix Enters into Co-Development Agreement with Japan Lifeline 19

Endologix Plans to Raise Funds through Public Offering of Shares 20

Endologix Raises USD210 Million in Private Placement 21

Endologix Plans to Raise USD100 Million in Public Offering of Securities 22

Endologix Plans to Raise USD46.2 Million in Equity Offering of Shares 23

TriVascular Technologies Completes IPO For USD 89.7 Million 24

Endologix Completes Public Offering Of Common Stock For USD 40 Million 26

Endologix Raises USD125 Million in Public Offering of 3.25% Notes Due 2020 27

TriVascular Raises USD10 Million in Private Placement 29

Endologix Completes Public Offering Of Notes Due 2018 For USD 86.3 Million 30

Endologix Acquires TriVascular Technologies 32

Endologix Inc, Key Competitors 34

Endologix Inc, Key Employees 35

Endologix Inc, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Endologix Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17980
Site License
USD 500 INR 35960
Corporate User License
USD 750 INR 53940

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com